Godavari Biorefineries Ltd has been granted a patent by the Japanese Patent Office for its invention, "5-Hydroxy-1,4-naphthalenedione for use in the treatment of cancer." The patent, numbered 7869786, was registered on May 26, 2026, and covers a novel class of compounds that exhibit strong inhibitory effects on cancer and cancer stem cells. This development strengthens the company's intellectual property portfolio in the biotechnology and pharmaceutical domain.

Patent Grant Details

The patent application, numbered 2023-525533, was originally filed on October 26, 2021. The inventors listed on the patent include Sandeep Gawade, Sangeeta Srivastava, Prashant Karkal, and Maithili Atavale. The patent specifically addresses the compound's efficacy against multiple types of cancer, including breast and prostate cancer.

Significance of the Development

Receiving the patent from Japan represents formal recognition of the novelty and inventiveness of Godavari Biorefineries Ltd's cancer treatment compound. Patents in the pharmaceutical and biotechnology sectors serve as critical markers of innovation, providing the company with exclusive intellectual property rights over the compound in the Japanese jurisdiction. The acknowledgment of the compound's strong effects on cancer and stem cells highlights its scientific distinction within the oncology space.

Godavari Biorefineries Ltd returned to profitability in FY26, recording a net profit of ₹3.5 crore against a net loss of ₹23.4 crore in the previous fiscal year. Revenue from operations for the year stood at ₹1,987.9 crore, up 6.3% from ₹1,870.3 crore in FY25. The turnaround was driven by a resilient performance across its integrated bio-refinery segments, despite a challenging operating environment marked by elevated cane and feedstock costs in the fourth quarter. The audited standalone and consolidated financial results were approved by the board on May 22, 2026, and published in newspapers on May 24, 2026, pursuant to Regulation 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

For the quarter ended March 31, 2026, the company posted a net profit of ₹52.9 crore, compared to ₹71.9 crore in the same quarter of the previous year. Total income for Q4 FY26 was ₹570 crore, while EBITDA stood at ₹92.1 crore, with margins contracting to 16.2% from 20.7% a year ago.

Financial Performance

The company's total income for FY26 increased to ₹2,000.2 crore from ₹1,886.9 crore in FY25. Profit before exceptional items and tax for the year was ₹35.7 crore, a significant improvement from the loss of ₹1.5 crore reported in the previous year. The following table summarises the key annual and quarterly financial metrics:

Operational Highlights

During the 2025-26 crushing season, the company achieved its highest-ever cane crushing of 2.5 Mn tonnes. The Integrated Sugar, Cogen & Ethanol segment reported an EBITDA of ₹83.9 crore for Q4 FY26, while the Bio Based Chemicals segment recorded an EBITDA of ₹9.5 crore. The consumer business, Jivana, revenues crossed ₹129 crore in FY26 compared to ₹108 crore in FY25.

Segment-wise revenue for FY26 showed growth across key verticals. The Bio-Based Chemicals segment revenue grew 6.6% to ₹578 crore, while the Integrated Sugar, Co-gen & Ethanol segment revenue increased 5.8% to ₹1,383.2 crore. The company also strengthened its innovation portfolio with the grant of a Japanese patent related to antiviral therapeutics during the quarter.

Strategic Updates

Management provided an update on its 200 KLPD grain-based distillery, stating that commissioning trials are scheduled for June 2026. The facility is expected to add approximately 60 million liters of annual ethanol capacity. The company reported that almost all equipment is on site and the plant is erected. The multi-feedstock flexibility is expected to mitigate climate, policy, and feedstock risks once operational.

Regarding its bio-based chemicals segment, the company noted that while geopolitical disruptions impacted sales, competitiveness continues to improve through debottlenecking and process optimization. Management indicated a stronger outlook for the current financial year due to a narrowing gap between fossil and renewable prices, supported by the company's bagasse-based energy platform.

Pursuant to Regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of the earnings conference call for Q4 and FY26 has been uploaded on the company website.